Tenax Therapeutics Company
Tenax Therapeutics maintains an oxygen supply to stop disease and damage to tissues that occurs when the flow of oxygen is interrupted. Tenax Therapeutics is developingmedical products designed to deliver oxygen to specific tissues in the body that are deprived of oxygen. Oxycyte PFC is in Phase IIb clinical trials in Switzerland and Israel for traumatic brain injury. Tenax Therapeutics is developing a PFC-based topical cream that has potential benefits for dermatologic indications and wounds. Studies in this area were completed in India. Tenax Therapeutics has developed the DERMACYTE line of skin care products to address several common aging issues, such as fine lines, wrinkles, puffiness, skin tone, blemishes and more.
Technology:
Specific disorder-related
Industry:
Treatment range
Headquarters:
Morrisville, USA
Founded Date:
01.01.1967
Employees Number:
11-50
Funding Status:
IPO
Total Funding:
$10 650 000
Estimated Revenue:
$10-50 Mn
Last Funding Date:
30.06.2020
Last Funding Type:
Post-IPO Secondary
Register and Claim Ownership